Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database
Jung Y, Kim M, Li H, Lee K, Koyanagi A, Solmi M, Kronbichler A, Dragioti E, Tizaoui K, Cargnin S, Terrazzino S, Hong S, Ghayda R, Kim N, Chung S, Jacob L, Salem J, Yon D, Lee S, Kostev K, Kim A, Jung J, Choi J, Shin J, Park S, Choi S, Ban K, Moon S, Go Y, Shin J, Smith L. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clinical And Translational Science 2021, 15: 501-513. PMID: 34719115, PMCID: PMC8841455, DOI: 10.1111/cts.13168.Peer-Reviewed Original ResearchConceptsFood and Drug AdministrationAdverse drug reactionsAssociated with remdesivirHPSC-CMsWorld Health OrganizationUS Food and Drug AdministrationInternational pharmacovigilance databaseAnalysis to patientsDose-dependent mannerIn vitro dataCV-ADRTreatment of coronavirus disease 2019Cardiovascular eventsCardiac arrestOdds ratioPharmacovigilance databaseRemdesivir useIn vitro experimentsDrug reactionsDisproportionality analysisDrug AdministrationMultiple confoundersCV consequencesCV monitoringCoronavirus disease 2019
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply